Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

Abstract Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual checkpoint blockade may improve treatment activity. Dune (NCT03095274) is a non-randomized controlled multicohort phase II clinical trial evaluating durvalumab plus tremelimumab activi...

詳細記述

書誌詳細

主要な著者:	J. Capdevila, J. Hernando, A. Teule, C. Lopez, R. Garcia-Carbonero, M. Benavent, A. Custodio, A. Garcia-Alvarez, A. Cubillo, V. Alonso, A. Carmona-Bayonas, T. Alonso-Gordoa, G. Crespo, P. Jimenez-Fonseca, M. Blanco, A. Viudez, A. La Casta, I. Sevilla, A. Segura, M. Llanos, S. Landolfi, P. Nuciforo, J. L. Manzano
フォーマット:	Artigo
言語:	Inglês
出版事項:	Nature Portfolio 2023-05-01
シリーズ:	Nature Communications
オンライン･アクセス:	https://doi.org/10.1038/s41467-023-38611-5
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!